DANIELLI, RICCARDO
 Distribuzione geografica
Continente #
NA - Nord America 1.891
EU - Europa 1.375
AS - Asia 789
SA - Sud America 105
Continente sconosciuto - Info sul continente non disponibili 75
AF - Africa 31
OC - Oceania 1
Totale 4.267
Nazione #
US - Stati Uniti d'America 1.859
RU - Federazione Russa 379
SG - Singapore 329
CN - Cina 223
IT - Italia 222
GB - Regno Unito 218
IE - Irlanda 213
BR - Brasile 85
VN - Vietnam 84
DE - Germania 78
SE - Svezia 71
FR - Francia 65
HK - Hong Kong 57
UA - Ucraina 46
FI - Finlandia 24
ZA - Sudafrica 24
ES - Italia 22
BD - Bangladesh 15
CA - Canada 15
KR - Corea 15
MX - Messico 11
IN - India 10
PL - Polonia 7
AR - Argentina 6
CO - Colombia 6
JP - Giappone 6
AZ - Azerbaigian 5
NL - Olanda 5
PK - Pakistan 5
AT - Austria 4
IQ - Iraq 4
TR - Turchia 4
BE - Belgio 3
EC - Ecuador 3
LT - Lituania 3
MY - Malesia 3
NP - Nepal 3
SA - Arabia Saudita 3
UZ - Uzbekistan 3
BG - Bulgaria 2
BH - Bahrain 2
CH - Svizzera 2
HR - Croazia 2
ID - Indonesia 2
KZ - Kazakistan 2
LB - Libano 2
LK - Sri Lanka 2
NG - Nigeria 2
OM - Oman 2
PA - Panama 2
SK - Slovacchia (Repubblica Slovacca) 2
AL - Albania 1
AU - Australia 1
BO - Bolivia 1
BY - Bielorussia 1
CI - Costa d'Avorio 1
CL - Cile 1
CR - Costa Rica 1
CZ - Repubblica Ceca 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
EE - Estonia 1
EG - Egitto 1
GR - Grecia 1
IL - Israele 1
IR - Iran 1
JM - Giamaica 1
KH - Cambogia 1
LA - Repubblica Popolare Democratica del Laos 1
MA - Marocco 1
MK - Macedonia 1
MU - Mauritius 1
NO - Norvegia 1
PH - Filippine 1
PY - Paraguay 1
SY - Repubblica araba siriana 1
TH - Thailandia 1
TL - Timor Orientale 1
TT - Trinidad e Tobago 1
UY - Uruguay 1
VE - Venezuela 1
Totale 4.192
Città #
Fairfield 232
Dublin 213
Singapore 200
Southend 182
Ashburn 159
Dallas 144
San Jose 111
Woodbridge 100
Moscow 95
Houston 94
Cambridge 91
Seattle 88
Santa Clara 84
Beijing 79
Wilmington 78
Hong Kong 57
Milan 56
Siena 50
Jacksonville 44
Chandler 40
Ann Arbor 39
Council Bluffs 34
Princeton 33
The Dalles 31
Shanghai 29
Los Angeles 27
New York 26
Ho Chi Minh City 25
Lauterbourg 22
Johannesburg 21
Helsinki 19
Rome 19
San Mateo 18
Málaga 17
Hanoi 15
Dearborn 14
San Diego 13
Hefei 12
Dong Ket 11
Munich 11
Nanjing 11
San Francisco 10
Florence 9
Denver 8
Brooklyn 7
Buffalo 7
Düsseldorf 7
Montreal 7
Orem 7
Palermo 7
Phoenix 7
Seoul 7
Stockholm 7
Boston 6
London 6
Poplar 6
São Paulo 6
Yongsan-gu 6
Avon 5
Baku 5
Chicago 5
Columbus 5
Frankfurt am Main 5
Nanchang 5
Toronto 5
Venezia 5
Warsaw 5
Da Nang 4
Figino 4
Labico 4
Mexico City 4
Norwalk 4
Porto Alegre 4
Redondo Beach 4
Tokyo 4
Amsterdam 3
Asciano 3
Atlanta 3
Boardman 3
Bogotá 3
Brussels 3
Dhaka 3
Guangzhou 3
Kunming 3
Naples 3
Ninh Bình 3
Pistoia 3
Portsmouth 3
Redwood City 3
Rio de Janeiro 3
Riyadh 3
Tashkent 3
Vienna 3
Abuja 2
Ankara 2
Araras 2
Bari 2
Barnet 2
Benito Juarez 2
Bologna 2
Totale 2.909
Nome #
Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy) 359
Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme 337
Long-term follow up of metastatic melanoma patients treated with Thymosin alpha-1: investigating immune checkpoints synergy 277
Adjuvant vemurafenib in resected, BRAF V600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial 265
Circulating levels of PD-L1 in mesothelioma patients from the NIBIT-MESO-1 study: Correlation with survival 263
Ipilimumab in pretreated metastatic uveal melanoma patients: safety and clinical efficacy 255
Guadecitabine plus ipilimumab in unresectable melanoma: the NIBIT-M4 clinical trial 237
Epigenetically regulated clonal heritability of CTA expression profiles in human melanoma 216
“Cancer Bio-Immunotherapy in Siena”: Eleventh Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 17–19, 2013 206
Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategies 198
Ipilimumab in the common daily practice: feasibility, safety, efficacy and long-term follow-up in heavily pretreated metastatic melanoma patients 195
Clinical studies with anti-CTLA-4 antibodies in non-melanoma indications 192
Immunotherapy targeting immune check-point(s) in brain metastases 186
Clinical Efficacy of the Anti-Cytotoxic T Lymphocyte Antigen-4 (CTLA-4) Monoclonal Antibody Ipilimumab in Pretreated Metastatic Uveal Melanoma Patients 184
Eruptive porokeratosis under nivolumab adjuvant treatment for melanoma 181
Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian network for tumor biotherapy (NIBIT)-M1 phase II study 168
ICOS expression as immunologic marker in immune activating monoclonal antibodies 152
Efficacy of ipilimumab plus nivolumab or ipilimumab plus fotemustine vs fotemustine in patients with melanoma metastatic to the brain: Primary analysis of the phase III NIBIT-M2 trial 149
Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: An open-label, single-arm, phase 2 study 126
Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study 121
Totale 4.267
Categoria #
all - tutte 13.187
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 13.187


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022202 0 0 23 5 11 12 14 14 13 32 28 50
2022/2023265 19 22 50 20 9 45 10 28 16 18 15 13
2023/2024318 11 7 52 12 7 72 121 4 0 0 14 18
2024/2025520 15 24 57 21 73 37 4 20 92 17 54 106
2025/20261.478 93 125 106 206 430 67 152 38 23 62 42 134
2026/2027131 59 33 39 0 0 0 0 0 0 0 0 0
Totale 4.267